Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis — Joan Martí‐Fàbregas (2022) | RDL Network
Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis
Article 2022 en
Authors
JM
Joan Martí‐Fàbregas
PC
Pol Camps‐Renom
JB
Jonathan G. Best
Abstract
1 min read
Patients with IS or TIA with cSS are at increased risk of stroke (ICrH or IS) during follow-up; the risk of IS exceeds that of ICrH for patients receiving antiplatelet or anticoagulant treatment alone, but the risk of ICrH exceeds that of IS in patients receiving both treatments. The findings suggest that either antiplatelet or anticoagulant treatment alone should not be avoided in patients with cSS, but combined antithrombotic therapy might be hazardous. Our findings need to be confirmed by randomized clinical trials.
Luís Prats‐Sánchez, Pol Camps‐Renom, Philip S. Nash, Duncan Wilson, Gareth Ambler, Jonathan G. Best, Marina Guasch‐Jiménez, Anna Ramos‐Pachón, Alejandro Martínez‐Domeño, Álvaro Lambea‐Gil, Garbiñe Ezcurra‐Díaz, Daniel Guisado‐Alonso, Houwei Du, Rustam Al‐Shahi Salman, Hans Rolf Jäger, Professor Gregory Lip, Hakan Ay, Simon Jung, Natan M. Bornstein, Thomas Gattringer, Sebastian Eppinger, Dianne H.K. van Dam-Nolen, Masatoshi Koga, Ḱazunori Toyoda, Felix Fluri, Thanh G. Phan, Velandai Srikanth, Ji Hoe Heo, Hee‐Joon Bae, Peter J. Kelly, Toshio Imaizumi, Julie Staals, ,
Maurizio Paciaroni, Giancarlo Agnelli, A Bertolini, Alessandro Pezzini, Alessandro Padovani, Valeria Caso, Michele Venti, Andrea Alberti, Rosa Palmiero, Paolo Cerrato, Giorgio Silvestrelli, Alessia Lanari, Paolo Previdi, Francesco Corea, Alessandro Balducci, Roberto Ferri, Francesca Falcinelli, Esmeralda Filippucci, Paolo Chiocchi, Fábio Grandi, Laura Ferigo,
Discussion(0)
No comments yet. Be the first to comment.